Montelukast Aurobindo

Montelukast, the active ingredient in Montelukast Aurobindo, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children as directed by a healthcare professional.

GNH USA supplies Montelukast Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Our distribution network ensures timely delivery and compliance with local regulatory requirements.

Montelukast acts on the leukotriene pathway to control inflammation and bronchoconstriction in several respiratory conditions.

Asthma: reduces frequency of wheezing episodes and improves lung function. Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea

Serious or Rare Side Effects: - Angioedema or severe allergic reactions - Neuropsychiatric events such as agitation, depression, or suicidal thoughts - Hepatic injury, including elevated transaminases

Montelukast should be used with careful clinical monitoring.

Assess liver function: consider baseline hepatic enzymes before initiating therapy. Monitor neuropsychiatric symptoms: watch for mood changes, anxiety, or suicidal thoughts. Avoid use in patients with known hypersensitivity to montelukast or any tablet excipients. Use caution in severe renal impairment: dose adjustment may be required. Pregnancy and lactation: evaluate risk–benefit ratio as safety data are limited. Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole): may increase montelukast plasma concentrations. - Potent enzyme inducers (e.g., phenobarbital, rifampin): may markedly reduce efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: montelukast may potentiate anticoagulant effect; monitor INR. - Theophylline: possible additive bronchial effects; observe respiratory status. - Beta‑agonists: combined therapy may increase risk of tachycardia.